These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27650859)

  • 21. PCSK9 inhibitors- A new age in lipid management?
    Grant PJ
    Diab Vasc Dis Res; 2017 May; 14(3):171. PubMed ID: 28467196
    [No Abstract]   [Full Text] [Related]  

  • 22. New concepts in the management of dyslipidaemiaa.
    Gencer B; Rodondi N; Mach F
    Swiss Med Wkly; 2016; 146():w14378. PubMed ID: 27878791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a).
    Vuorio A; Watts GF; Kovanen PT
    Eur Heart J; 2017 Dec; 38(48):3555-3559. PubMed ID: 29029165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New approaches for the treatment of dyslipidemia].
    Mostaza JM; Lahoz C
    Med Clin (Barc); 2014 Apr; 142(7):306-9. PubMed ID: 23768860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.
    Arrieta A; Page TF; Veledar E; Nasir K
    PLoS One; 2017; 12(1):e0169761. PubMed ID: 28081164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients.
    Zamora A; Masana L; Comas-Cufi M; Plana N; Vila À; García-Gil M; Alves-Cabratosa L; Elosua R; Marrugat J; Ramos R
    Rev Esp Cardiol (Engl Ed); 2018 Dec; 71(12):1010-1017. PubMed ID: 29606363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia.
    Whayne TF
    Am J Cardiovasc Drugs; 2016 Apr; 16(2):83-92. PubMed ID: 26596726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia.
    Sible AM; Nawarskas JJ; Anderson JR
    Cardiol Rev; 2016; 24(3):141-52. PubMed ID: 26886466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update of Clinical Trials of Anti-PCSK9 Antibodies.
    Wu NQ; Li S; Li JJ
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.
    Page MM; Watts GF
    Diabetes Obes Metab; 2018 Feb; 20(2):270-282. PubMed ID: 28736830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antibodies in addition to statin therapy lowers LDL cholesterol].
    Bossenmayer S
    Dtsch Med Wochenschr; 2012 Sep; 137(36):1728. PubMed ID: 23281534
    [No Abstract]   [Full Text] [Related]  

  • 35. PCSK9 Inhibitors: Economics and Policy.
    Hlatky MA; Kazi DS
    J Am Coll Cardiol; 2017 Nov; 70(21):2677-2687. PubMed ID: 29169476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alirocumab for the treatment of hypercholesterolaemia.
    Della Pepa G; Bozzetto L; Annuzzi G; Rivellese AA
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):571-582. PubMed ID: 28395555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Unmet needs: patients with statin intolerance or familial hypercholesterolemia].
    Masana L; Civeira F
    Clin Investig Arterioscler; 2016 May; 28 Suppl 2():22-30. PubMed ID: 27888902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anti-PCSK9 antibodies in type 2 diabetes and secondary prevention of cardiovascular diseases].
    López-Miranda J; Pintó X
    Clin Investig Arterioscler; 2016 May; 28 Suppl 2():31-38. PubMed ID: 27888904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Spanish interdisciplinary committee for cardiovascular disease prevention and the spanish society of cardiology position statement on dyslipidemia management. Differences between the European and american guidelines].
    Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR;
    Semergen; 2015 Apr; 41(3):149-57. PubMed ID: 25450438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.